Kirkiin: A New Toxic Type 2 Ribosome-Inactivating Protein from the Caudex of Adenia kirkii

• Published in: Toxins Vol. 13; no. 2; p. 81
• Main Authors: Bortolotti, Massimo, Maiello, Stefania, Ferreras, José M, Iglesias, Rosario, Polito, Letizia, Bolognesi, Andrea
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI 22.01.2021; MDPI AG
• Subjects: Adenia; apoptosis; kirkiin; lectins; neuroblastoma; ribosome-inactivating proteins; toxic enzymes; ricin; kirkiin; lectins; neuroblastoma; apoptosis; ribosome-inactivating proteins; Adenia
• ISSN: 2072-6651; 2072-6651
• DOI: 10.3390/toxins13020081

Ribosome-inactivating proteins (RIPs) are plant toxins that irreversibly damage ribosomes and other substrates, thus causing cell death. RIPs are classified in type 1 RIPs, single-chain enzymatic proteins, and type 2 RIPs, consisting of active A chains, similar to type 1 RIPs, linked to lectin B chains, which enable the rapid internalization of the toxin into the cell. For this reason, many type 2 RIPs are very cytotoxic, ricin, volkensin and stenodactylin being the most toxic ones. From the caudex of (Mast.) Engl., a new type 2 RIP, named kirkiin, was purified by affinity chromatography on acid-treated Sepharose CL-6B and gel filtration. The lectin, with molecular weight of about 58 kDa, agglutinated erythrocytes and inhibited protein synthesis in a cell-free system at very low concentrations. Moreover, kirkiin was able to depurinate mammalian and yeast ribosomes, but it showed little or no activity on other nucleotide substrates. In neuroblastoma cells, kirkiin inhibited protein synthesis and induced apoptosis at doses in the pM range. The biological characteristics of kirkiin make this protein a potential candidate for several experimental pharmacological applications both alone for local treatments and as component of immunoconjugates for systemic targeting in neurodegenerative studies and cancer therapy.